Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 50 | SFEBES2017 | Next issue

Society for Endocrinology BES 2017

Harrogate, UK
06 Nov 2017 - 08 Nov 2017

Card image cap
SfE BES 2017 will be on the 6-8 November 2016 in Harrogate, UK.

Poster Presentations

Neoplasia, Cancer and Late Effects

ea0050p241 | Neoplasia, Cancer and Late Effects | SFEBES2017

Population remodeling in the acquisition of endocrine resistance in breast cancer

Hu Rong , Sengupta Surojeet , Sevigny Catherine , Zhang Zhen , Wang Yue , Clarke Robert

The cell-cell interactions that occur within the breast tumor microenvironment are critical determinants of cancer cell fate. In the face of treatment, the theory of clonal evolution dominates current thinking. Thus, individual cells may acquire a mutation(s) that provides a selection advantage, i.e., Darwinian selection acts at the single cell level. We studied the effect of antiestrogen treatment on the population remodeling ...

ea0050p242 | Neoplasia, Cancer and Late Effects | SFEBES2017

Combination of JQ1, an inhibitor of epigenetic pathways, and everolimus for treatment of pancreatic and bronchial neuroendocrine tumours

Lines Kate E , Stevenson Mark , Filippakopoulos Panagis , Grozinsky-Glasberg Simona , Bountra Chas , Thakker Rajesh V

Current treatments, including surgery, medical therapy, radiotherapy, and radionuclide therapy for neuroendocrine tumours of the pancreas (PNETs) and bronchus (BNETs) are often unsatisfactory, leading to a 5-year survival of <50% and 5%, respectively. PNETs and BNETs frequently have mutations in chromatin-remodelling genes and the protein encoded by the multiple endocrine neoplasia type 1 (MEN1) gene, menin. Menin binds the...

ea0050p243 | Neoplasia, Cancer and Late Effects | SFEBES2017

Analysis of the diagnosis, treatment and genetics of 175 cases of phaeochromocytoma and paraganglioma in two ENETS Centres of Excellence

Stoenchev Kostadin , McDonald Basil , Dean Sophie , Canham Natalie , Palazzo Fausto , Banga Neal , Clarke Peter , Harcourt Jonathan , Baker Darryl , Todd Jeannie , Martin Niamh , Wernig Florian , Chahal Harvinder , Sam Amir , Hatfield Emma , Dhillo Waljit , Meeran Karim , Grossman Ashley , Toumpanakis Christos , Caplin Martyn , Tan Tricia , Khoo Bernard

Background: Phaeochromocytomas (PCC) and paragangliomas (PGL) are tumours derived from neural crest cells within the adrenal medulla or extra-adrenal ganglia, respectively. Over 20 known genes are implicated in at least 30% of cases. Experience with these tumours in individual centres is limited due to their rarity.Objective: To describe the demographics, genetics, treatment and progression-free survival (PFS) in ...

ea0050p245 | Neoplasia, Cancer and Late Effects | SFEBES2017

Assessment of protective factors from the development of radiation induced hypopituitarism: A single centre study

Kulendrarajah Bavidra , Marland Anne , Davies Dawn-Marie , Foord Tina , Jafar-Mohammadi Bahram

Pituitary irradiation is a known risk factor for the development of subsequent hormonal dysfunction. However, it has been noted that some patients do not appear to be affected after many years of follow up. The aim of this retrospective study was to identify protective factors from developing radiation induced hypopituitarism (RIH).Methods: This is a single center study of patients attending the late effects of ch...

ea0050p246 | Neoplasia, Cancer and Late Effects | SFEBES2017

The course of the endocrine disease in POEMS syndrome

Caimari Francisca , D'Sa Shirley , Lunn Michael , Keddie Stephen , Baldeweg Stephanie E

Introduction: POEMS syndrome is a rare multisystem disorder characterised by polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-proliferative disorder and skin changes among other features. We describe the course of the endocrine disease in the context of this paraneoplastic syndrome.Methods: Of the 60 patients with POEMS care in hospital, data are available for 43 patients who attended the Joint POEM...

ea0050p247 | Neoplasia, Cancer and Late Effects | SFEBES2017

Check point inhibitor monoclonal antibody therapy – Are there effective markers for endocrine immune-related adverse events?

Anguelova Lia , Dhere Archana , Payne Miranda , Turner Helen

Introduction: Whilst effective, targeted checkpoint inhibitor monoclonal antibodies are associated with immune-related adverse events including endocrinopathies. Increased licensed oncological indications for these agents raise the need for effective screening, monitoring and ongoing treatment of endocrinopathies. The aim of our study was to investigate potential predictive factors that may identify patients at risk of endocrinopathies....

ea0050p248 | Neoplasia, Cancer and Late Effects | SFEBES2017

In-house method for the detection of miRNA 145 and 21 in plasma samples of breast cancer patients using SYBR green reverse transcription-qPCR

Samuel Titilola , James Babatunde , Negedu Sunday , Balogun Adepeju , Magbagbeola Olubunmi

Background: A major challenge in the management of breast cancer (BC) is the search for biomarkers that are sensitive and less invasive. miRNAs are reported to be tissue-specific, stable and aberrantly expressed in different tumours, hence their emerging role as potential biomarkers in BC management.Objective: The study focused on developing an in-house method for the detection of mir-145 and mir-21 using SYBR Gre...

ea0050p249 | Neoplasia, Cancer and Late Effects | SFEBES2017

Multiple endocrine neoplasia type 1 (MEN1) phenocopy due to a P.Leu380Phe cell division cycle 23 (CDC73) mutation

Lines Kate E , Nachtigall Lisa B , Dichtel Laura E , Cranston Treena , Khairi Shafaq , Boon Hannah , Sagvand Babak Torabi , Zhang Xun , Stevenson Mark , Klibanski Anne , Thakker Rajesh V

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the combined occurrence of parathyroid tumours, and neuroendocrine tumours (NETs) of the pituitary and pancreas. MEN1 is caused by mutations of the tumour suppressor gene MEN1, and MEN1 germline mutations are found in >75% of MEN1 patients. The remaining 25% of patients may have mutations involving as yet unidentified gene...

ea0050p250 | Neoplasia, Cancer and Late Effects | SFEBES2017

Immunotherapy and development of endocrine dysfunction: An audit of immune checkpoint inhibitors

Abhi Dhruv , Vennam Sarath , Dugal Tabinda , Edeghere Simon

Introduction: Immune checkpoint inhibitors such as CTLA 4 inhibitors (Ipilimumab) and PD1 inhibitors (Nivolumab/ Pembrolizumab) are being increasingly used for treatment of malignant melanomas and other solid tumours. Despite clinical benefits, they have been known to cause certain Immune related adverse effects (IrAEs) which may be dermatological, gastrointestinal, endocrine, or other immune phenomenon.The endocr...

ea0050p251 | Neoplasia, Cancer and Late Effects | SFEBES2017

Endocrinopathies are a frequent Consequence of Immune Checkpoint Inhibitor Therapy, with a Low Recovery Rate of both Thyroid and Pituitary Dysfunction

McGowan Anne , Weatherby Tom , Powlson Andrew , Parkinson Christine , Chatterjee Krishna , Corrie Pippa , Moran Carla

Background: Immune checkpoint (CTLA-4, PD-1) inhibitors are increasingly used to treat cancers including advanced melanoma. Although endocrine immune related adverse events (IRAEs) are now well reported, the frequency and type of thyroid and pituitary dysfunction reported varies considerably, with hypophysitis after CTLA-4 inhibitors reported in 2–16%, and thyroid dysfunction after PD-1 inhibitors in 2–39%. In addition, recove...

ea0050p252 | Neoplasia, Cancer and Late Effects | SFEBES2017

Primary pulmonary typical carcinoid as a source of ectopic Adrenocorticotropic hormone (ACTH)-dependant Cushing’s

Esparza Maria , Panach Kamaldeep , Butt Yasmeen , Abramowitz Jessica , Torrealba Jose , Hashim Ibrahim

Ectopic ACTH is rare and represents about 10% of causes of Cushing’s syndrome. Associated tumours are neuroendocrine in origin and include small cell lung cancer, carcinoid tumours, and medullary carcinoma of the thyroid. In this report, we describe a rare case of ectopic ACTH due to a primary pulmonary carcinoid tumour.A 29 years old male was diagnosed with hypertension 18 months prior to presentation. On ex...

ea0050p253 | Neoplasia, Cancer and Late Effects | SFEBES2017

Challenges in diagnosis and management of tumour induced oncogenic osteomalacia

Sewell Gavin , Qureshi Sheharyar , Aslam Roohi , Lepore Mario , Patel Bhavik , Nimri Adib , Kaushal Rashmi

The combination of hypophosphataemia and hypercalcaemia has numerous aetiologies, which can be challenging in the clinical setting. Careful early biochemical identification will facilitate appropriate further imaging and management. We report a case of a gentleman who presented in his ninth decade with deteriorating cognition, proximal muscle weakness and reduced mobility on a background of hypertension, type 2 diabetes with associated ...